<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment-wise, after the SARS and MERS epidemics a few antivirals were proposed and tested and among these are mycophenolic acid, cyclosporine at low concentrations, chloroquine; chlorpromazine, loperamide, and lopinavir, found to be broad-spectrum coronavirus inhibitors (
 <xref rid="b17-ijmm-46-02-0489" ref-type="bibr">17</xref>). Recently FDA has approved remdesivir (GS5734 - an RNA polymerase inhibitor) as specific treatment for COVID-19; different protocols use chloroquine (500 mg q 12 h); hydroxychloroquine (200 mg q 12 h); lopinavir/ritonavir (400/100 mg every 12 h), Î±-interferon (aerosol inhalation 5 million IUbid), and there are &gt;50 treatments tested in clinical trials (
 <xref rid="b18-ijmm-46-02-0489" ref-type="bibr">18</xref>).
</p>
